Alban Bessede

Aryl hydrocarbon receptor control of a disease tolerance defence pathway

Alban Bessede, Marco Gargaro, Maria Teresa Pallotta et al. · Nature · 2014 · 670 citations · Full text

Life Sciences, Molecular Genetics, Cell Signaling +11

Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression

Lucile Vanhersecke, Maxime Brunet, Jean‐Philippe Guégan et al. · Nature Cancer · 2021 · 569 citations · Full text

Life Sciences, Immunology, Oncology +17

Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas

Maud Toulmonde, Nicolas Penel, Julien Adam et al. · JAMA Oncology · 2017 · 394 citations · Full text

Medicine, Immunology, Oncology +17

The kynurenine pathway is activated in human obesity and shifted toward kynurenine monooxygenase activation

Marie Favennec, Benjamin Hennart, Robert Caïazzo et al. · Obesity · 2015 · 271 citations

Life Sciences, Biochemistry, Endocrinology +17

Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort

Antoîne Italiano, Alban Bessede, M. Pulido et al. · Nature Medicine · 2022 · 263 citations

Medicine, Immunology, Oncology +13